CAPS - Capstone Therapeutics Corp.

Other OTC - Other OTC Delayed Price. Currency in USD

Capstone Therapeutics Corp.

1275 West Washington Street
Suite 104
Tempe, AZ 85281
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. John M. Holliman IIIExec. Chairman & Principal Exec. Officer129kN/A1954
Mr. Leslie M. TaegerSr. VP, CFO and Principal Accounting & Financial Officer83kN/A1951
Dr. Randolph C. SteerConsultantN/AN/A1950
Mr. Wardell M. WilliamHead of Clinical & Regulatory Review BoardN/AN/A1939
Ms. Karen StruckInvestor Relations ProfessionalN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Corporate Governance

Capstone Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.